Replies to post #12300 on The Rising Influence of Rising Affluence

[DewDiligence]

ABSORB's biggest benefit is that it eliminates the risk of late stent thrombosis and obviates the need to take antiplatelet drugs for years (which means forever for some patients).

However, ABSORB is harder to implant than XIENCE (ABT's market-leading conventional stent), so there's a long-term vs short-term tradeoff that doctors and patients need to make.

[DewDiligence]

ABT withdraws ABSORB stent from EU market (with limited exceptions):

http://epvantage.com/Universal/View.aspx?type=Story&id=699747&isEPVantage=yes

This is a rare commercial setback for ABT, who invested a lot in the development of ABSORB and the bioabsorbable-stent technology on which it is based. Although ABSORB is still on the market in the US, the sales are apt to be small following the data reported in #msg-129683267.

ABT is trading flat today.